Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Brodalumab - AstraZeneca/Bausch Health Companies/Kyowa Kirin

Drug Profile

Brodalumab - AstraZeneca/Bausch Health Companies/Kyowa Kirin

Alternative Names: AMG-827; KHK-4827; Kyntheum; LP 0160; LUMICEF; SILIQ; Siliq

Latest Information Update: 25 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Amgen; AstraZeneca; Bausch Health Companies; Kyowa Hakko Kirin; Kyowa Kirin; LEO Pharma
  • Class Anti-inflammatories; Antiasthmatics; Antipsoriatics; Antirheumatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 17 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Erythrodermic psoriasis; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis
  • Registered Psoriasis
  • Phase III Axial spondylarthritis; Palmoplantar pustulosis; Systemic scleroderma
  • Discontinued Asthma; Crohn's disease; Rheumatoid arthritis

Most Recent Events

  • 18 Nov 2019 Kyowa Kirin announces intention to submit IND to regulatory authorities for Axial spondyloarthritis in Japan and Asia in 2020 or 2021 (Kyowa Kirin pipeline, November 2019)
  • 30 Sep 2019 Preregistration in Psoriasis in Macau, China (SC)
  • 13 Aug 2019 Brodalumab sub-licensed to Leo Pharma for development and commercialisation in Australia, Brazil, Egypt, Mexico, Russia and Saudi Arabia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top